Evotec Collaborated with Sernova to Develop iPSC-Based Beta Cell Replacement Therapy for the Treatment of Diabetes
Shots:
- Evotec has invested $20.96M in Sernova & will contribute to cell manufacturing along with clinical development funding. Both companies will share profits equally & Evotec participates in the clinical research program
- Sernova to acquire an exclusive option to license Evotec's iPSC-based beta cells for use with its Cell Pouch system to treat diabetes. The pre-clinical development program will be jointly funded until IND acceptance
- The collaboration will combine Evotec's iPSC-based beta cells with Sernova's cell pouch device to develop off-the-shelf iPSC-based beta cell replacement therapy for insulin-dependent diabetes. Sernova is currently conducting a P-I/II study at the University of Chicago
Ref: Accesswire | Image: Evotec
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
